Corteva, Inc. (NYSE:CTVA) Receives Average Rating of “Moderate Buy” from Brokerages

Corteva, Inc. (NYSE:CTVA) has been given an average recommendation of “Moderate Buy” by the twenty-three brokerages that are currently covering the firm, MarketBeat.com reports. Nine investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $91.50.

Several equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft restated a “buy” rating and set a $101.00 target price on shares of Corteva in a report on Monday, August 3rd. Royal Bank Of Canada reaffirmed an “overweight” rating on shares of Corteva in a research report on Friday. JPMorgan Chase & Co. upped their price target on shares of Corteva from $77.00 to $83.00 and gave the stock a “neutral” rating in a research report on Monday, August 3rd. Mizuho raised their price objective on Corteva from $96.00 to $97.00 and gave the stock an “outperform” rating in a report on Tuesday, July 14th. Finally, Jefferies Financial Group lifted their target price on shares of Corteva from $95.00 to $97.00 in a report on Thursday, May 7th.

Hedge Funds Weigh In On Corteva

Institutional investors have recently made changes to their positions in the business. EFG International AG acquired a new position in Corteva in the second quarter worth $25,000. Compass Financial Management LLC acquired a new position in shares of Corteva during the second quarter worth approximately $25,000. JPL Wealth Management LLC bought a new position in shares of Corteva in the third quarter worth $25,000. Garton & Associates Financial Advisors LLC acquired a new position in Corteva during the 4th quarter valued at about $27,000. Finally, Bank of Jackson Hole Trust bought a new stake in Corteva during the fourth quarter worth approximately $28,000. 81.54% of the stock is owned by institutional investors and hedge funds.

Corteva Stock Up 1.0%

CTVA opened at $84.74 on Tuesday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.10 and a current ratio of 1.52. The company has a market cap of $56.54 billion, a price-to-earnings ratio of 56.12, a PEG ratio of 2.58 and a beta of 0.57. Corteva has a one year low of $60.53 and a one year high of $90.97. The business’s fifty day moving average is $82.81 and its two-hundred day moving average is $80.66.

Corteva (NYSE:CTVA) last announced its quarterly earnings results on Thursday, July 30th. The company reported $2.30 earnings per share for the quarter, beating analysts’ consensus estimates of $2.24 by $0.06. The business had revenue of $6.38 billion during the quarter, compared to analysts’ expectations of $6.60 billion. Corteva had a return on equity of 10.18% and a net margin of 5.66%.The business’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the business posted $2.20 earnings per share. Corteva has set its FY 2026 guidance at 3.600-3.800 EPS. Analysts anticipate that Corteva will post 3.72 EPS for the current fiscal year.

Corteva Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Tuesday, September 1st will be paid a dividend of $0.18 per share. The ex-dividend date of this dividend is Tuesday, September 1st. This represents a $0.72 annualized dividend and a yield of 0.8%. Corteva’s payout ratio is 47.68%.

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.